Cyxone
0.019
SEK
-26.92 %
CYXO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-26.92%
-47.22%
-54.22%
-80.53%
-79.25%
-83.39%
-99.52%
-99.54%
-99.63%
cyxone.com/en/investor-relations
Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CYXO
Daily low / high price
0.018 / 0.026
SEK
Market cap
7.13M SEK
Turnover
82.41K SEK
Volume
4M
Financial calendar
Annual report
25.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 5.9 % | 5.9 % |
| Försäkringsaktiebolaget Skandia | 2.4 % | 2.4 % |
| Nordnet Pensionsförsäkring | 2.2 % | 2.2 % |
| ABBMO Holding AB | 2.2 % | 2.2 % |
| Christian Pettersson | 2.1 % | 2.1 % |
| Ivar Nordqvist | 2.1 % | 2.1 % |
| Göran Ofsén | 1.9 % | 1.9 % |
| Oxy Pharma AB | 1.6 % | 1.6 % |
| SHB Luxemburg | 1.4 % | 1.4 % |
| Tage Larsson | 1.4 % | 1.4 % |
ShowingAll content types
Cyxone AB publishes outcome of rights issue
The subscription period in Cyxone's rights issue starts today
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools